Shares of KOSDAQ-listed T&R Biofab were strong early on the 28th on news that the company announced next-generation artificial organ manufacturing technology.
As of 9:34 a.m. that day, T&R Biofab was trading at 3,580 won, up 150 won (4.37%) from the previous session.
Regenerative medicine company T&R Biofab said that before the regular session opened that day, together with researchers at Korea University of Technology and Education, it fabricated a cell block including blood vessels (Organ Building Block, OBB) in 3D and assembled it to implement an artificial organ, and published the platform technology in the international journal in biomaterials, "Materials Today Bio."
The company said the platform, which can expand organs by block units, is evaluated as a new approach that improves the structural and functional limitations of existing artificial organ manufacturing technologies.
Sim Jin-hyeong, director (CTO) of T&R Biofab, said, "This study is a case in which ultra-precision bioprinting technology suggested a new possibility for artificial organ manufacturing," adding, "The method of assembling cell blocks with predesigned blood vessels will become a core technology for realizing artificial organs more stably and closer to real organs in the future."